Nothing Special   »   [go: up one dir, main page]

ES2604778T3 - Gránulos de oseltamivir fosfato y método de preparación de los mismos - Google Patents

Gránulos de oseltamivir fosfato y método de preparación de los mismos Download PDF

Info

Publication number
ES2604778T3
ES2604778T3 ES06775361.6T ES06775361T ES2604778T3 ES 2604778 T3 ES2604778 T3 ES 2604778T3 ES 06775361 T ES06775361 T ES 06775361T ES 2604778 T3 ES2604778 T3 ES 2604778T3
Authority
ES
Spain
Prior art keywords
oseltamivir phosphate
preparation
phosphate granules
weight
granules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06775361.6T
Other languages
English (en)
Inventor
Song Li
Wu Zhong
Junhai Xiao
Yunde Xie
Xingzhou Li
Hao Cui
Zhibing Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Pharmacology and Toxicology of AMMS
Original Assignee
Institute of Pharmacology and Toxicology of AMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Pharmacology and Toxicology of AMMS filed Critical Institute of Pharmacology and Toxicology of AMMS
Application granted granted Critical
Publication of ES2604778T3 publication Critical patent/ES2604778T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Gránulos de oseltamivir fosfato, que tienen una composición de: oseltamivir fosfato 3,28% peso sacarosa 94,72% peso povidona k30 2,00% peso

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES06775361.6T 2006-04-04 2006-08-11 Gránulos de oseltamivir fosfato y método de preparación de los mismos Active ES2604778T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200610066995 2006-04-04
CN2006100669957A CN1820744B (zh) 2006-04-04 2006-04-04 磷酸奥司他韦颗粒剂及其制备方法
PCT/CN2006/002043 WO2007112619A1 (fr) 2006-04-04 2006-08-11 Granule de phosphate d'oseltamivir et son procédé de préparation

Publications (1)

Publication Number Publication Date
ES2604778T3 true ES2604778T3 (es) 2017-03-09

Family

ID=36922416

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06775361.6T Active ES2604778T3 (es) 2006-04-04 2006-08-11 Gránulos de oseltamivir fosfato y método de preparación de los mismos

Country Status (7)

Country Link
US (1) US9034382B2 (es)
EP (1) EP2005945B1 (es)
JP (1) JP5222841B2 (es)
KR (1) KR101303325B1 (es)
CN (1) CN1820744B (es)
ES (1) ES2604778T3 (es)
WO (1) WO2007112619A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183583A1 (en) * 2006-02-20 2012-09-27 Chugai Pharmaceutical Co Ltd Pharmaceutical composition comprising oseltamivir phosphate
CN1820744B (zh) 2006-04-04 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 磷酸奥司他韦颗粒剂及其制备方法
WO2010143207A1 (en) 2009-06-11 2010-12-16 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals
CN103315965B (zh) * 2013-07-11 2015-08-05 河南中帅医药科技股份有限公司 一种适用于婴幼儿及儿童的口服固体颗粒及其制备方法
CN104940125A (zh) * 2014-03-28 2015-09-30 广东东阳光药业有限公司 一种磷酸奥司他韦的固体制剂
KR20160002177A (ko) * 2014-06-30 2016-01-07 한미약품 주식회사 오셀타미비어 유리염기를 포함하는 약학 조성물
CN104138355A (zh) * 2014-08-06 2014-11-12 广东东阳光药业有限公司 一种磷酸奥司他韦干混悬剂及其制备方法
KR20160038837A (ko) * 2014-09-30 2016-04-07 한미약품 주식회사 오셀타미비어 함유 과립, 그 과립을 포함하는 캡슐제, 및 이들의 제조방법
WO2016088010A1 (en) * 2014-12-01 2016-06-09 Lupin Atlantis Holdings Sa Oseltamivir compositions
KR20160117070A (ko) * 2015-03-31 2016-10-10 한미약품 주식회사 오셀타미비어 함유 경구용 고형제제 및 그 제조방법
CN106236728A (zh) * 2015-06-03 2016-12-21 广东东阳光药业有限公司 一种磷酸奥司他韦分散型胶囊及其制备方法
WO2018004261A1 (ko) * 2016-06-30 2018-01-04 한미약품 주식회사 오셀타미비어 함유 경구용 고형제제 및 그 제조방법
JP6778051B2 (ja) * 2016-08-18 2020-10-28 沢井製薬株式会社 オセルタミビルリン酸塩含有医薬組成物
KR20200106607A (ko) * 2019-03-05 2020-09-15 주식회사 코아팜바이오 오셀타미비르 함유 의약 조성물
CN113603606A (zh) * 2021-08-25 2021-11-05 北京睿悦生物医药科技有限公司 一种磷酸奥司他韦干混悬剂杂质的制备方法
CN114262278B (zh) * 2021-12-20 2023-09-26 北京阳光诺和药物研究股份有限公司 一种制备磷酸奥司他韦的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4422433A1 (de) 1994-06-28 1996-01-04 Cognis Bio Umwelt Mehrenzymgranulat
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
CN1310999A (zh) * 2000-02-29 2001-09-05 布里斯托尔-迈尔斯斯奎布公司 低剂量艾替开韦制剂及其应用
BRPI0112014B1 (pt) * 2000-06-27 2016-09-13 Hoffmann La Roche processo para a preparação de uma composição farmacêutica na forma de estruturas semelhantes à esponja ou espuma e porosas, e, composição farmacêutica
US6605302B2 (en) * 2001-07-17 2003-08-12 Osmotica Corp. Drug delivery device containing oseltamivir and an H1 antagonist
AR034813A1 (es) * 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
JP3881640B2 (ja) 2003-08-08 2007-02-14 塩野義製薬株式会社 ロラタジンを含むドライシロップ剤
EP1602730A3 (en) * 2004-06-04 2006-01-25 DSM IP Assets B.V. Biosynthetic production of 4-amino-4-deoxychorismate (ADC) and [3R,4R]-4-amino-3-hydroxycyclohexa-1,5-diene-1-carboxylic acid (3,4-CHA)
SG183583A1 (en) * 2006-02-20 2012-09-27 Chugai Pharmaceutical Co Ltd Pharmaceutical composition comprising oseltamivir phosphate
CN1820744B (zh) 2006-04-04 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 磷酸奥司他韦颗粒剂及其制备方法

Also Published As

Publication number Publication date
EP2005945A4 (en) 2012-12-19
CN1820744A (zh) 2006-08-23
US20090176877A1 (en) 2009-07-09
KR101303325B1 (ko) 2013-09-03
EP2005945A2 (en) 2008-12-24
JP5222841B2 (ja) 2013-06-26
CN1820744B (zh) 2011-01-26
WO2007112619A1 (fr) 2007-10-11
EP2005945A9 (en) 2009-07-01
KR20080109020A (ko) 2008-12-16
JP2009532390A (ja) 2009-09-10
EP2005945B1 (en) 2016-10-12
US9034382B2 (en) 2015-05-19

Similar Documents

Publication Publication Date Title
ES2604778T3 (es) Gránulos de oseltamivir fosfato y método de preparación de los mismos
CL2018003398A1 (es) Composición farmacéutica de liberación sostenida que comprende micro-partículas. (divisional de solicitud 2013-03538).
ES2566391T3 (es) Composiciones a base de hidrofluoroolefinas
ES2522567T3 (es) Composición farmacéutica que comprende amlodipino y losartán
CL2009000882A1 (es) Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer.
DK2277509T3 (da) DPP IV inhibitorformuleringer
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
CL2007001992A1 (es) Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege
BRPI0815170A2 (pt) Composição farmacêutica que compreende um inibidor de sglt 2
DOP2009000257A (es) Inhibidores de cinasa p70 s6
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
AR054114A1 (es) Composiciones farmaceuticas que comprenden imatinib y un retardador de la liberacion
UY30302A1 (es) Formulaciones de pepticuerpos terapeuticos liofilizados
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
ATE444748T1 (de) 1-ä(3-hydroxy-adamant-1-ylamino)-acetylü- pyrrolidin-2(s)-carbonitril-formulierung mit modifizierter freisetzung
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
MA31218B1 (fr) Forme galenique secable permettant une liberation modifiee du principe actif
RS54485B1 (en) C7-FLUORO SUBSTITUTED TETRACYCLINE UNITS
UY32126A (es) Composición farmacéutica sólida
DK2086932T3 (da) Substituerede aryl-indol forbindelser og deres kynurenin/kynuramin-lignende metabolitter som terapeutiske midler
MEP10209A (en) Stable emulsion composition
RS54158B1 (en) AMILOID BINDING AGENTS
BRPI0810399A2 (pt) Composto, composição farmacêutica que o contém e uso do mesmo